TABLE OF CONTENTS

- Description p.1
- Audience p.1
- Impact Factor p.1
- Abstracting and Indexing p.2
- Editorial Board p.2
- Guide for Authors p.5

DESCRIPTION

The European Journal of Cancer (EJC) integrates preclinical, translational, and clinical research in cancer, from epidemiology, carcinogenesis and biology through to innovations in cancer treatment and patient care. The journal publishes original research, reviews, previews, editorial comments and correspondence.

The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society of Breast Cancer Specialists (EUSOMA).

AUDIENCE

Basic and preclinical researchers, clinical oncologists (medical, paediatric, radiation, surgical), translational oncologists, cancer epidemiologists.

IMPACT FACTOR

2018: 6.680 © Clarivate Analytics Journal Citation Reports 2019
ABSTRACTING AND INDEXING

PubMed/Medline
Cambridge Scientific Abstracts
Chemical Abstracts
Current Clinical Cancer
Current Contents
Current Contents
Research Alert
Web of Science
Toxicology Abstracts
CINAHL
Elsevier BIOBASE
Embase
BIOSIS Citation Index
Pascal Francis
Current Contents - Life Sciences
Current Contents - Clinical Medicine
Science Citation Index
Reference Update
CAB International
CAB Health
UMI Microfilms
Scopus

EDITORIAL BOARD

Editor-in-Chief
Alexander M. M. Eggermont, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

Editor: Basic Science and Preclinical Research
Ulrich Keilholz, Charite University Hospital Berlin Centre 10 Charite Comprehensive Cancer Center, Berlin, Germany

Editor: Epidemiology and Prevention
Valery E. Lemmens, Eindhoven, Netherlands

Editor: Tumour Immunotherapy
Aurelien Marabelle, Villejuif, France

Editors: Breast Cancer
Giuseppe Curigliano, European Institute of Oncology, Milano, Italy
Suzette Delaloge, Gustave Roussy, Villejuif, France

Editors: Gastrointestinal Cancers
Michel Ducrœux, Gustave Roussy, Villejuif, France
Volker Heinemann, Ludwig Maximilians University Munich, Munich, Germany

Editor: Genitourinary Cancers
Karim Fizazi, Gustave Roussy Department of Oncological Medicine, Villejuif, France

Editor: Head and Neck Cancer
Jean-Pascal Machiels, University Hospital Saint-Luc, Bruxelles, Belgium

Editor: Hemato-Oncology
Roch Houot, Rennes, France

Editor: Lung Cancer
Martin Schuler, University of Duisburg-Essen - Campus Essen, Essen, Germany

Editor: Gynaecological Cancers
Ignace Vergote, KU Leuven University Hospitals Leuven, Leuven, Belgium
Editor: Endocrine, Sarcomas and Other Rare Tumours
Stefan Sleijfer, Erasmus MC Cancer Centre, Rotterdam, Netherlands

Editor: Melanoma
Dirk Schadendorf, University of Duisburg-Essen - Campus Essen, Essen, Germany

Editor: Neuro-oncology
Martin van den Bent, Erasmus MC Cancer Centre, Rotterdam, Netherlands

Editor: Paediatric Oncology
Rob Pieters, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

Editorial Office
EJC Editorial Office, Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK

Clinical Oncology Editorial Board
A.C.J. van Akkooi, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands
Richard Baird, University of Cambridge, Cambridge, United Kingdom
Raffaele Califano, The Christie NHS Foundation Trust, Manchester, United Kingdom
Emiliano Calvo, START International Inc., Madrid-CIOCC, Ctro Integral Oncológico Clara Campal, Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain
Fatima Cardoso, Champalimaud Foundation, Lisboa, Portugal
Elisabeth G De Vries, Academic Medical Centre Groningen, Groningen, Netherlands
Adam Dicker, Thomas Jefferson University, Philadelphia, United States
Reinhard Dummer, University of Zurich, Zurich, Switzerland
Sara Erridge, The University of Edinburgh, Edinburgh, United Kingdom
Hans Gelderblom, Leids Universitair Medisch Centrum (LUMC), Dept. of Clinical Oncology, Leiden, Netherlands
Birgit Georger, INSERM U749, Villejuif, France
John Haanen, Amsterdam, The Netherlands
Baktiar Hasan, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
Jean-Claude Horiot, Institut Multidisciplinaire d'Oncologie, Genolier clinic, Genolier, Switzerland
Dirk Jäger, German Cancer Research Centre, Heidelberg, Germany
Artur Katz, Syrian-Lebanese Hospital, Sao Paulo, Brazil
Paul Lorigan, Christie Hospital, Manchester, United Kingdom
Yohann Loriot, INSERM U749, Villejuif, France
Christophe Massard, INSERM U749, France
Kerrie McDonald, University of New South Wales, Sydney, Australia
Françoise Meunier, Federation of European Academies of Medicine (FEAM), Brussels, Belgium
Tony Mok, The Chinese University of Hong Kong, Dept. of Clinical Oncology, Shatin, Hong Kong
Do-Hyun Nam, Sungkyunkwan University, Jongno-gu, South Korea
James Perry, Sunnybrook Research Institute, Toronto, Canada
Achim Rody, University of Lubeck, Lubeck, Germany
Manuela Schmidinger, Medical University of Vienna, Vienna, Austria
Jean-Charles Soria, INSERM U749, Villejuif, France
Silvia Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Cancer Medicine Department, Adult mesenchymal tumour & Rare cancer Medical Oncology Unit, Milan, Italy
Cora Sternberg, Vincenzo Pansadoro Foundation, Roma, Italy
Eric Van Cutsem, KU Leuven Department of Oncology, Leuven, Belgium
Galina Velikova, University of Leeds, Leeds, United Kingdom
Eric Winquist, London Health Sciences Centre, London, Canada
Timothy Yap, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, United States

Basic Science and Preclinical Research Editorial Board
Paola Allavena, Humanitas Research Hospital Cellular Immunology Lab, Rozzano, Italy
John Anderson, University College London Institute of Child Health, London, United Kingdom
Massimo Broggini, Mario Negri Institute for Pharmacological Research Branch of Milan, Milan, Italy
Christophe Caux, Centre Léon Bérard, Dept. of Medical Oncology, Lyon, France
Manel Esteller, Bellvitge University Hospital, Barcelona, Spain
Enrico Garattini, Mario Negri Institute for Pharmacological Research Branch of Milan, Milan, Italy
J.M. Irish, Vanderbilt University School of Medicine, United States
H.E.K. Kohrt †, STANFORD UNIVERSITY, United States
John Lunec, Newcastle University, Newcastle Upon Tyne, United Kingdom
Antonia Maria Müller, University of Zurich, Zurich, Switzerland
Daniel Olive, Aix-Marseille University, Marseille, France
Athanasios Papavassiliou, National and Kapodistrian University of Athens School of Health Sciences, Athens, Greece
Giorgio Parmiani, San Raffaele Hospital, Milano, Italy
Victoria Sanz-Moreno, King's College London, London, United Kingdom
Sheila Singh, McMaster University, Canada
John Stagg, University of Montreal, Canada
Amaya Virós, Cancer Research UK, Macclesfield, United Kingdom
Britta Weigelt, MEMORIAL SLOAN KETTERING CANCER CENTER, New York, United States
Nadia Zaffaroni, Fondazione IRCCS Istituto Nazionale Tumori, Department of Applied Research and Technological Development, Milano, Italy

Epidemiology and Prevention Editorial Board
Philippe Autier, International Prevention Research Institute, Écully, France
Marianne Berwick, NM, USA
Nirmala Bhoo Pathy, Kuala Lumpur, Malaysia
Paolo Boffetta, Icahn School of Medicine at Mount Sinai, New York, United States
Cristina Bosetti, Mario Negri Institute for Pharmacological Research Branch of Milan, Milano, Italy
Emanuele Crocetti, Florence, Italy
Christine Friedenreich, University of Calgary, Calgary, Canada
Gemma Gatta, Milan, Italy
Iris Lansdorp-Vogelaar, Erasmus University Rotterdam, Rotterdam, Netherlands
Marc Maynadié, University Hospital Centre Dijon, Dijon, France
Henrik Møller, King's College London, London, United Kingdom
Eleni Petridou, National and Kapodistrian University of Athens, Athens, Greece
Lonneke van de Poll-Franse, Catharina Hospital, Eindhoven, Netherlands
Marjanka Schmidt, Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, Netherlands
Isabelle Soerjomataram, International Agency for Research on Cancer, Lyon, France
Esther de Vries, Erasmus University Rotterdam, Rotterdam, Netherlands

Paediatric Oncology Editorial Board
Christophe Bergeron, Institute of Paediatric Haematology and Oncology, Lyon, France
Eric Bouffet, Hospital for Sick Children, Toronto, Canada
Mitchell Cairo, New York Medical College, Valhalla, United States
Guillermo Chantada, Hospital JP Garrahan, Buenos Aires, Argentina
Francois Doz, Institute Curie, Paris, France
Andrea Ferrari, National Cancer Institute IRCCS Pascale Foundation, Napoli, Italy
Martha Grootenhuis, Academic Medical Center, Amsterdam, Netherlands
Marry van den Heuvel-Eibrink, Erasmus University Rotterdam, Rotterdam, Netherlands
Max van Noesel, Erasmus MC Sophia Children Hospital, Rotterdam, Netherlands
Kathy Pritchard-Jones, University College London, London, United Kingdom
Lillian Sung, Hospital for Sick Children, Toronto, Ontario, Canada
GUIDE FOR AUTHORS

INTRODUCTION

The European Journal of Cancer (EJC) integrates preclinical, translational, and clinical research in cancer, from epidemiology, carcinogenesis and biology through to innovations in cancer treatment and patient care. The journal publishes original research, reviews, previews, editorial comments and correspondence.

The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society of Breast Cancer Specialists (EUSOMA).

Types of paper

Original research articles:
Original research articles have a limit of 2,500 words and no more than 40 references. Authors are asked to provide a structured abstract of no more than 250 words and a list of keywords.

Current Perspectives:
Current Perspectives have a limit of 2,000 words with an unlimited number of tables and figures and a limit of 30 references. Authors should provide an unstructured abstract of no more than 250 words and a list of keywords.

Correspondence:
Letters to the Editor which comment directly on work that has previously been published in the EJC will be considered. The author of the paper on which the letter is commenting will be contacted and invited to respond. In addition, the EJC will consider letters on unique cases or observations of interest to the journal's readership, particularly with regard to side effects from new treatment modalities such as immunotherapy. Letters have a limit of 1,000 words, 5 authors, 10 references and may have up to 1 figure or 1 table. They should be structured as a letter, without an abstract or keywords.

The EJC also publishes review articles, preview articles, editorial comments and a special series of biennial reports on topics of interest to the journal's readership. These are commissioned by the Editors. Prospective authors who wish to discuss any of these article types are invited to contact the Editorial Office (ejcancer@elsevier.com).

Contact details for submission

Manuscripts and the accompanying Author Form should be submitted online at http://ees.elsevier.com/ejc and the instructions on the site should be closely followed. Authors may submit manuscripts and track their progress to final decision. Reviewers can download manuscripts and submit their reports to the Editors.

The full contact details for the Editorial Office are shown below:

European Journal of Cancer
Elsevier Ltd
The Boulevard, Langford Lane
Oxford OX5 1GB
UK
Tel: +44 (0)1865 843282
Fax: +44 (0)1865 843977
Email: ejcancer@elsevier.com

In a covering letter, please identify the person responsible for editorial correspondence (address, telephone and fax numbers and e-mail address).

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:

**Manuscript:**
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

**Graphical Abstracts / Highlights files** (where applicable)

**Supplemental files** (where applicable)

Further considerations
- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](http://www.elsevier.com/locate/ejca).

**BEFORE YOU BEGIN**

**Ethics in publishing**
Please see our information pages on [Ethics in publishing](http://www.elsevier.com/locate/ejca) and [Ethical guidelines for journal publication](http://www.elsevier.com/locate/ejca).

**Reporting guidelines**
Certain research designs should be reported in manuscripts submitted to the EJC according to reporting guidelines: CONSORT for randomized controlled trials; STROBE for observational studies; PRISMA for systematic reviews and meta-analysis; and STARD for diagnostic studies. The appropriate checklist should be submitted at the time of the article submission. All reporting guidelines can be found at the EQUATOR network site: [http://www.equator-network.org/reporting-guidelines](http://www.equator-network.org/reporting-guidelines).

**Reporting clinical trials**
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.

**Registration of clinical trials**
Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with [International Committee of Medical Journal Editors](http://www.elsevier.com/locate/ejca) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.
**Studies in humans and animals**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms *sex* and *gender* should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

**Microarray data**

The data should be made available to our readers/reviewers through a MIAME compliant online database or at least a website address.

**Biomarkers**


**Conflict of Interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places:

1. A summary Conflict of interest Statement in a separate Word document. This should include any detail that may be considered a conflict of interest for all authors. If there are no interests to declare for any of the authors then please state this: ‘Declarations of interest: none’. This summary statement will be ultimately published if the article is accepted so needs to be in an editable Word format. Please ensure it includes enough information for researchers as they will not have access to the forms.
2. Detailed disclosures within separate Conflict of Interest / ICMJE forms. It is important for potential interests to be declared in both places and that the information matches. Please click here for more information. These form(s) will not be published and are for the review process and the journal's official records only.

**Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.
Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Author form
The corresponding author must submit a completed Author Form with their submission. The form enables the corresponding author to record the contribution of each author and confirms whether ethical approval for the study has been sought, whether funding for the study was provided and whether there are any conflicts of interest. It must be signed by the corresponding author and uploaded to EES with the manuscript.

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Open access
Please visit our Open Access page for more information.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article
Please submit your article via http://www.ees.elsevier.com/ejc.

Referees
Please submit, with the manuscript, the names, addresses and e-mail addresses of five potential referees. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

PREPARATION

Peer review
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Introduction - State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.
Material and methods - Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.
Results - Results should be clear and concise.
Discussion - This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions - The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices - If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

**Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) written in full, middle name(s) in initials and family name(s) written in full of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration, e.g. "Yang L. Wang (???)". Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

The title page should also include details of sources of support in the form of grants, equipment, and drugs.

**Highlights**

Highlights are mandatory for this journal for all article types except Letters to the Editor, Invited Previews or Editorial Comments. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site, but please note that despite the general information given there, for this journal, highlights are mandatory for all article types with the only exceptions being Letters to the Editor, Invited Previews or Editorial Comments.

**Abstract**

The second page should start with the abstract, which should be up to a maximum of 250 words and must include the aim of the study, a brief summary of the methods, results and a concluding statement.

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 x 1328 pixels (h x w) or proportionally more. The image should be readable at a size of 5 x 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site. Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

**Keywords**

Include up to 10 key words from the Medical Subject Headings from *Index Medicus*
Acknowledgements
All contributors who do not meet the criteria for authorship as defined by the ICMJE should be listed in an acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should dislose whether they had any writing assistance and identify the entity that paid for this assistance.

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapted (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

Illustration services
Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References

Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
http://open.mendeley.com/use-citation-style/european-journal-of-cancer
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples of Formatted References).
Revised manuscripts
Authors who have been asked to revise their manuscript by the Editors should submit a file which clearly shows the changes that have been made via the 'track changes' function or text highlighting, and a clean copy of the revised manuscript (i.e. a file which contains the changes without any highlighting). Authors are requested not to upload a copy of the original manuscript.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

Data linking
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Mendeley Data**
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

**Data statement**
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**AFTER ACCEPTANCE**

**Online proof correction**
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier’s Author Services. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.